Testing a new drug for wet macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have wet macular degeneration that has not been treated yet, including certain types like retinal angiomatous proliferation or polypoidal choroidal vasculopathy.
- Your diagnosis must have been made within the last 3 weeks before starting the study.
- You cannot have had any prior laser treatment in the study eye.
- You cannot have had cataract surgery, glaucoma surgery, or laser capsulotomy in the study eye within the last 3 months.
- You must not have uncontrolled glaucoma or high blood pressure.
- You cannot have received any previous injections of anti-VEGF medicines (like Avastin, Lucentis, or Eylea) into the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.